Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Esomeprazole

Targets (1)Enzymes (2)Biointeractions (4)

Identification

Name

Esomeprazole

Accession Number

DB00736 (APRD00363)

Type

Small Molecule

Groups

Approved, Investigational

Description

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]

Structure

Similar Structures

Synonyms

(−)-omeprazole
(S)-(−)-omeprazole
(S)-omeprazole
Esomeprazol
Ésoméprazole
Esomeprazolum
Omeprazole S-form
Perprazole

External IDs

A02BC05 / H 199/18

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Esomeprazole magnesium	925R0D7W1O	161973-10-0	KWORUUGOSLYAGD-YPPDDXJESA-N
Esomeprazole magnesium dihydrate	36H71644EQ	217087-10-0	DBOUSUONOXEWHU-VCKZSRROSA-N
Esomeprazole magnesium trihydrate	R6DXU4WAY9	217087-09-7	VEVZQDGATGBLIC-UHFFFAOYSA-N
Esomeprazole sodium	L2C9GWQ43H	161796-78-7	RYXPMWYHEBGTRV-JIDHJSLPSA-N
Esomeprazole strontium	SCC2RK476A	914613-86-8	FEVPVZSYBDUVGY-YPPDDXJESA-N
Esomeprazole strontium hydrate	C5N25H3803	934714-36-0	NCGHIAKEJNQSMS-QLGOZJDFSA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Esomeprazole	Tablet, delayed release	20 mg	Oral	Teva	2015-11-09	Not applicable
Act Esomeprazole	Tablet, delayed release	40 mg	Oral	Teva	2015-11-09	Not applicable
Esomeprazole	Tablet, delayed release	40 mg	Oral	Sanis Health Inc	2014-09-22	Not applicable
Esomeprazole	Tablet, delayed release	20 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable
Esomeprazole	Tablet, delayed release	20 mg	Oral	Ethypharm	Not applicable	Not applicable
Esomeprazole	Tablet, delayed release	20 mg	Oral	Teva	Not applicable	Not applicable
Esomeprazole	Tablet, delayed release	40 mg	Oral	Pro Doc Limitee	2012-11-22	Not applicable
Esomeprazole	Tablet, delayed release	40 mg	Oral	Sivem Pharmaceuticals Ulc	2015-07-22	Not applicable
Esomeprazole	Tablet, delayed release	20 mg	Oral	Sivem Pharmaceuticals Ulc	2015-07-22	Not applicable
Esomeprazole	Tablet, delayed release	20 mg	Oral	Pro Doc Limitee	2013-06-06	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Anodyne Ile	Kit			Fortus Pharma, Llc	2017-10-16	Not applicable
Apo-esomeprazole	Tablet, delayed release	40 mg	Oral	Apotex Corporation	2011-03-07	Not applicable
Apo-esomeprazole	Tablet, delayed release	20 mg	Oral	Apotex Corporation	2012-03-02	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	40 mg/1	Oral	North Star Rx Llc	2017-08-14	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Amerincan Health Packaging	2017-03-15	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	40 mg/1	Oral	Torrent Pharmaceuticals Limited	2015-10-19	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Aurobindo Pharma	2016-04-21	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 1/1	Oral	Nu Care Pharmaceuticals,inc.	2015-10-19	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	40 1/1	Oral	Remedy Repack	2016-12-07	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Camber Pharmaceuticals	2015-09-21	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Basic Care Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	L. Perrigo Company	2018-01-09	Not applicable
Berkley and Jensen Heartburn Treatment	Capsule, delayed release	20 mg/1	Oral	BJWC	2017-09-25	Not applicable
Careone Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	American Sales Company	2017-09-26	Not applicable
DG Health Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Dolgencorp	2017-09-22	Not applicable
Equaline Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Supervalu	2017-09-25	Not applicable
Equate Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Walmart Stores	2017-10-05	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Family Dollar	2017-10-16	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Walmart Stores	2017-10-16	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Kroger	2017-09-22	Not applicable
Esomeprazole Magnesium	Capsule, delayed release	20 mg/1	Oral	Sam's West, Inc	2017-10-16	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Mylan-naproxen/esomeprazole Mr	Esomeprazole (20 mg) + Naproxen (375 mg)	Tablet, delayed release	Oral	Mylan Pharmaceuticals	2017-02-27	Not applicable
Mylan-naproxen/esomeprazole Mr	Esomeprazole (20 mg) + Naproxen (500 mg)	Tablet, delayed release	Oral	Mylan Pharmaceuticals	2017-02-10	Not applicable
Vimovo	Esomeprazole (20 mg) + Naproxen (375 mg)	Tablet, delayed release	Oral	Astra Zeneca	2011-02-04	Not applicable
Vimovo	Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1)	Tablet, delayed release	Oral	Stat Rx USA	2011-07-01	2018-02-08
Vimovo	Esomeprazole magnesium (20 mg/1) + Naproxen (500 mg/1)	Tablet, delayed release	Oral	Astra Zeneca Lp	2010-07-06	2017-03-31
Vimovo	Esomeprazole magnesium (20 mg/1) + Naproxen (500 mg/1)	Tablet, delayed release	Oral	Horizon Pharma, Inc.	2014-01-01	Not applicable
Vimovo	Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1)	Tablet, delayed release	Oral	Astra Zeneca Lp	2010-07-06	2017-03-31
Vimovo	Esomeprazole (20 mg) + Naproxen (500 mg)	Tablet, delayed release	Oral	Astra Zeneca	2011-02-04	Not applicable
Vimovo	Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1)	Tablet, delayed release	Oral	Horizon Pharma, Inc.	2014-01-01	Not applicable

International/Other Brands

Alenia (Delta) / Awa-Block (Usawa) / Axagon (Simesa) / Cor (Prater) / Cronopep (Biotoscana) / Emanera (Krka) / Emep (Aristopharma) / Emozul (HYGIA) / ES-OD (Piramal Healthcare) / Esmep (HYGIA) / Eso (Asiatic Lab) / Esofag (Micro Labs) / Esogastrosedol (Nova Argentia) / Esolok (Ibn Sina) / Esomarfan (Marfan) / Esomenta (RAK) / Esomep (ACI) / Esomeprazol Genfar (Genfar S.A) / Esopral (Maquifarma) / Esorest (Centaur) / Inexium paranova / Lucen (Malesci) / Nexiam (AstraZeneca)

Categories

UNII

N3PA6559FT

CAS number

119141-88-7

Weight

Average: 345.416
Monoisotopic: 345.114712179

Chemical Formula

C₁₇H₁₉N₃O₃S

InChI Key

SUBDBMMJDZJVOS-DEOSSOPVSA-N

InChI

InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1

IUPAC Name

5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole

SMILES

COC1=CC2=C(NC(=N2)[[email protected]@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1

Pharmacology

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Structured Indications

Pharmacodynamics

Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Mechanism of action

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.

Target	Actions	Organism
APotassium-transporting ATPase alpha chain 1	inhibitor	Human

Absorption

90%

Volume of distribution

16 L [healthy volunteers]

Protein binding

97%

Metabolism

Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome P450 system via CYP2C19 and CYP3A4. Metabolism produces inactive hydroxy and desmethyl metabolites, which have no effect on gastric acid secretion. Less than 1% of the parent drug is excreted in urine.

Route of elimination

Approximately 80% of the administered dose of esomeprazole is excreted as metabolites in urine and the remaining 20% is excreted in feces.

Half life

1-1.5 hours

Clearance

Not Available

Toxicity

Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid heartbeat, sweating

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Esomeprazole Metabolism Pathway	Drug metabolism
Esomeprazole Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Cytochrome P450 2C19	CYP2C19*2	(A;A)	A Allele, homozygote	Effect Directly Studied	Patients with this genotype have reduced metabolism of esomeprazole.	Details
Cytochrome P450 2C19	CYP2C19*3	(A;A)	A Allele, homozygote	Effect Directly Studied	Patients with this genotype have reduced metabolism of esomeprazole.	Details
Cytochrome P450 2C19	CYP2C19*2A	Not Available	681G>A	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*2B	Not Available	681G>A	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*4	Not Available	1A>G	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*5	Not Available	1297C>T	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*6	Not Available	395G>A	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*7	Not Available	19294T>A	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*22	Not Available	557G>C / 991A>G	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*24	Not Available	99C>T / 991A>G … show all	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details
Cytochrome P450 2C19	CYP2C19*35	Not Available	12662A>G	Effect Inferred	Poor metabolizer, lower dose requirement, improved drug efficacy	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
Abiraterone	The metabolism of Esomeprazole can be decreased when combined with Abiraterone.	Approved
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Esomeprazole.	Approved, Investigational
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Esomeprazole.	Approved
Alendronic acid	The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.	Approved
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Esomeprazole.	Approved, Investigational
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Esomeprazole.	Approved, Investigational
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Esomeprazole.	Approved, Withdrawn
Amiodarone	The metabolism of Esomeprazole can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Esomeprazole.	Approved
Amoxicillin	The metabolism of Amoxicillin can be decreased when combined with Esomeprazole.	Approved, Vet Approved
Amphetamine	Esomeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Illicit, Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Esomeprazole.	Approved, Investigational
Apalutamide	The serum concentration of Esomeprazole can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	The metabolism of Apixaban can be decreased when combined with Esomeprazole.	Approved
Aprepitant	The serum concentration of Esomeprazole can be increased when it is combined with Aprepitant.	Approved, Investigational
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Esomeprazole.	Approved, Investigational
Armodafinil	The metabolism of Esomeprazole can be decreased when combined with Armodafinil.	Approved, Investigational
Artemether	The metabolism of Artemether can be decreased when combined with Esomeprazole.	Approved
Asunaprevir	The metabolism of Asunaprevir can be decreased when combined with Esomeprazole.	Approved, Investigational, Withdrawn
Atazanavir	Esomeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Atomoxetine	The metabolism of Esomeprazole can be decreased when combined with Atomoxetine.	Approved
Axitinib	The metabolism of Axitinib can be decreased when combined with Esomeprazole.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Esomeprazole.	Approved
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Esomeprazole.	Approved
Boceprevir	The metabolism of Esomeprazole can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The metabolism of Esomeprazole can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Esomeprazole can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Esomeprazole.	Approved
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Esomeprazole.	Approved, Investigational
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Esomeprazole.	Approved, Illicit, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Esomeprazole.	Approved
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Esomeprazole.	Approved, Investigational
Cannabidiol	The metabolism of Cannabidiol can be decreased when combined with Esomeprazole.	Approved, Investigational
Carbamazepine	The metabolism of Esomeprazole can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Esomeprazole.	Approved
Carisoprodol	The metabolism of Carisoprodol can be decreased when combined with Esomeprazole.	Approved
Cefditoren	The serum concentration of Cefditoren can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Ceritinib	The serum concentration of Esomeprazole can be increased when it is combined with Ceritinib.	Approved
Chloramphenicol	The metabolism of Esomeprazole can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlorpropamide	The metabolism of Chlorpropamide can be decreased when combined with Esomeprazole.	Approved, Investigational
Cholecalciferol	The metabolism of Esomeprazole can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Esomeprazole.	Approved, Investigational
Cimetidine	The metabolism of Esomeprazole can be decreased when combined with Cimetidine.	Approved, Investigational
Cisapride	The metabolism of Cisapride can be decreased when combined with Esomeprazole.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Esomeprazole.	Approved
Clarithromycin	The metabolism of Esomeprazole can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Esomeprazole can be decreased when combined with Clemastine.	Approved, Investigational
Clobazam	The metabolism of Clobazam can be decreased when combined with Esomeprazole.	Approved, Illicit
Clodronic Acid	The therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Esomeprazole.	Approved, Investigational, Vet Approved
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Esomeprazole.	Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Clopidogrel	Esomeprazole may decrease the antiplatelet activities of Clopidogrel.	Approved
Clorindione	The serum concentration of Clorindione can be increased when it is combined with Esomeprazole.	Experimental
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Esomeprazole.	Approved, Illicit
Clotrimazole	The metabolism of Esomeprazole can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Esomeprazole.	Approved
Cobicistat	The metabolism of Esomeprazole can be decreased when combined with Cobicistat.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Esomeprazole.	Approved, Investigational
Crizotinib	The metabolism of Esomeprazole can be decreased when combined with Crizotinib.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.	Approved, Investigational
Cyclosporine	The metabolism of Esomeprazole can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cysteamine	The therapeutic efficacy of Cysteamine can be decreased when used in combination with Esomeprazole.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.	Approved
Dabrafenib	The serum concentration of Dabrafenib can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Esomeprazole.	Approved, Investigational
Darunavir	The metabolism of Esomeprazole can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Deferasirox	The serum concentration of Esomeprazole can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Esomeprazole.	Approved
Desipramine	The metabolism of Desipramine can be decreased when combined with Esomeprazole.	Approved, Investigational
Dexlansoprazole	The metabolism of Dexlansoprazole can be decreased when combined with Esomeprazole.	Approved, Investigational
Dexmethylphenidate	Esomeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Dextroamphetamine	Esomeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Illicit
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Esomeprazole.	Approved
Diazepam	The metabolism of Diazepam can be decreased when combined with Esomeprazole.	Approved, Illicit, Investigational, Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Esomeprazole.	Approved, Vet Approved
Dicoumarol	The serum concentration of Dicoumarol can be increased when it is combined with Esomeprazole.	Approved
Dihydroergotamine	The metabolism of Esomeprazole can be decreased when combined with Dihydroergotamine.	Approved, Investigational
Diltiazem	The metabolism of Esomeprazole can be decreased when combined with Diltiazem.	Approved, Investigational
Diphenadione	The serum concentration of Diphenadione can be increased when it is combined with Esomeprazole.	Experimental
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Esomeprazole.	Approved, Investigational
Dopamine	The metabolism of Dopamine can be decreased when combined with Esomeprazole.	Approved
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Esomeprazole.	Approved
Doxepin	The metabolism of Doxepin can be decreased when combined with Esomeprazole.	Approved, Investigational
Doxycycline	The metabolism of Esomeprazole can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The metabolism of Dronabinol can be decreased when combined with Esomeprazole.	Approved, Illicit
Dronedarone	The metabolism of Esomeprazole can be decreased when combined with Dronedarone.	Approved
Efavirenz	The metabolism of Esomeprazole can be decreased when combined with Efavirenz.	Approved, Investigational
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Esomeprazole.	Approved, Investigational
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Esomeprazole.	Approved, Investigational
Enfuvirtide	The metabolism of Enfuvirtide can be decreased when combined with Esomeprazole.	Approved, Investigational
Enzalutamide	The serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Erythromycin	The metabolism of Esomeprazole can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Esomeprazole.	Approved, Investigational
Eslicarbazepine acetate	The metabolism of Esomeprazole can be decreased when combined with Eslicarbazepine acetate.	Approved
Estradiol	The metabolism of Estradiol can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Ethyl biscoumacetate	The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Esomeprazole.	Withdrawn
Etidronic acid	The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Esomeprazole.	Approved
Etizolam	The metabolism of Etizolam can be decreased when combined with Esomeprazole.	Approved
Etravirine	The metabolism of Etravirine can be decreased when combined with Esomeprazole.	Approved
Famotidine	The metabolism of Famotidine can be decreased when combined with Esomeprazole.	Approved
Ferric Carboxymaltose	Esomeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric pyrophosphate	Esomeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Fluconazole	The serum concentration of Esomeprazole can be increased when it is combined with Fluconazole.	Approved, Investigational
Fluindione	The serum concentration of Fluindione can be increased when it is combined with Esomeprazole.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Esomeprazole.	Approved, Illicit
Fluoxetine	The metabolism of Fluoxetine can be decreased when combined with Esomeprazole.	Approved, Vet Approved
Flutamide	The metabolism of Flutamide can be decreased when combined with Esomeprazole.	Approved, Investigational
Fluvoxamine	The metabolism of Esomeprazole can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	The metabolism of Formoterol can be decreased when combined with Esomeprazole.	Approved, Investigational
Fosamprenavir	The metabolism of Esomeprazole can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Esomeprazole can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Esomeprazole can be increased when combined with Fosphenytoin.	Approved, Investigational
Fusidic Acid	The serum concentration of Esomeprazole can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Gemfibrozil	The metabolism of Esomeprazole can be decreased when combined with Gemfibrozil.	Approved
Gliclazide	The metabolism of Gliclazide can be decreased when combined with Esomeprazole.	Approved
Glucosamine	The metabolism of Glucosamine can be decreased when combined with Esomeprazole.	Approved, Investigational
Glyburide	The metabolism of Glyburide can be decreased when combined with Esomeprazole.	Approved
Guanfacine	The metabolism of Guanfacine can be decreased when combined with Esomeprazole.	Approved, Investigational
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Esomeprazole.	Approved
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Esomeprazole.	Approved
Ibandronate	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.	Approved, Investigational
Ibuprofen	The metabolism of Ibuprofen can be decreased when combined with Esomeprazole.	Approved
Idelalisib	The metabolism of Esomeprazole can be decreased when combined with Idelalisib.	Approved
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Esomeprazole.	Approved
Imatinib	The metabolism of Esomeprazole can be decreased when combined with Imatinib.	Approved
Imipramine	The metabolism of Imipramine can be decreased when combined with Esomeprazole.	Approved
Indinavir	The serum concentration of Indinavir can be decreased when it is combined with Esomeprazole.	Approved
Indomethacin	The metabolism of Indomethacin can be decreased when combined with Esomeprazole.	Approved, Investigational
Iron	Esomeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Iron Dextran	Esomeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Vet Approved
Iron saccharate	Esomeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Isavuconazole	The serum concentration of Esomeprazole can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Esomeprazole can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoniazid	The metabolism of Esomeprazole can be decreased when combined with Isoniazid.	Approved, Investigational
Isradipine	The metabolism of Esomeprazole can be decreased when combined with Isradipine.	Approved, Investigational
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Ivacaftor	The serum concentration of Esomeprazole can be increased when it is combined with Ivacaftor.	Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Esomeprazole.	Approved, Investigational
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Esomeprazole.	Approved, Investigational
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Esomeprazole.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Esomeprazole.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Esomeprazole.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Esomeprazole.	Approved, Investigational
Lobeglitazone	The metabolism of Esomeprazole can be decreased when combined with Lobeglitazone.	Approved, Investigational
Lopinavir	The metabolism of Esomeprazole can be decreased when combined with Lopinavir.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Esomeprazole.	Approved
Lorpiprazole	The serum concentration of Esomeprazole can be increased when it is combined with Lorpiprazole.	Approved
Lovastatin	The metabolism of Esomeprazole can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Esomeprazole can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Esomeprazole can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The metabolism of Lumiracoxib can be decreased when combined with Esomeprazole.	Approved, Investigational
Macitentan	The metabolism of Macitentan can be decreased when combined with Esomeprazole.	Approved
Medical Cannabis	The metabolism of Medical Cannabis can be decreased when combined with Esomeprazole.	Experimental
Melatonin	The metabolism of Melatonin can be decreased when combined with Esomeprazole.	Approved, Nutraceutical, Vet Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Esomeprazole.	Investigational, Withdrawn
Meprobamate	The metabolism of Meprobamate can be decreased when combined with Esomeprazole.	Approved, Illicit
Mesalazine	The therapeutic efficacy of Mesalazine can be decreased when used in combination with Esomeprazole.	Approved
Methadone	The metabolism of Methadone can be decreased when combined with Esomeprazole.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Esomeprazole.	Approved
Methsuximide	The metabolism of Methsuximide can be decreased when combined with Esomeprazole.	Approved
Methylphenidate	Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Methylphenobarbital	The metabolism of Methylphenobarbital can be decreased when combined with Esomeprazole.	Approved
Metoprolol	The metabolism of Metoprolol can be decreased when combined with Esomeprazole.	Approved, Investigational
Mifepristone	The serum concentration of Esomeprazole can be increased when it is combined with Mifepristone.	Approved, Investigational
Mitotane	The serum concentration of Esomeprazole can be decreased when it is combined with Mitotane.	Approved
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Esomeprazole.	Approved, Investigational
Modafinil	The metabolism of Esomeprazole can be decreased when combined with Modafinil.	Approved, Investigational
Mycophenolic acid	The serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.	Approved
Nabiximols	The metabolism of Nabiximols can be decreased when combined with Esomeprazole.	Approved
Nefazodone	The metabolism of Esomeprazole can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy.	Approved
Netupitant	The serum concentration of Esomeprazole can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The metabolism of Esomeprazole can be increased when combined with Nevirapine.	Approved
Nicardipine	The metabolism of Esomeprazole can be decreased when combined with Nicardipine.	Approved, Investigational
Nicotine	The metabolism of Nicotine can be decreased when combined with Esomeprazole.	Approved
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Esomeprazole.	Approved, Investigational
Nilutamide	The metabolism of Nilutamide can be decreased when combined with Esomeprazole.	Approved, Investigational
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Esomeprazole.	Approved
Olaparib	The metabolism of Esomeprazole can be decreased when combined with Olaparib.	Approved
Omeprazole	The metabolism of Esomeprazole can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Osimertinib	The serum concentration of Esomeprazole can be increased when it is combined with Osimertinib.	Approved
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Esomeprazole.	Approved, Investigational
Oxiconazole	The metabolism of Oxiconazole can be decreased when combined with Esomeprazole.	Approved
Palbociclib	The serum concentration of Esomeprazole can be increased when it is combined with Palbociclib.	Approved, Investigational
Pamidronate	The therapeutic efficacy of Pamidronate can be decreased when used in combination with Esomeprazole.	Approved
Pantoprazole	The metabolism of Esomeprazole can be decreased when combined with Pantoprazole.	Approved
Pazopanib	The serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole.	Approved
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Esomeprazole.	Approved, Investigational
Pentobarbital	The metabolism of Esomeprazole can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Esomeprazole.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Esomeprazole.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Esomeprazole.	Withdrawn
Phenindione	The serum concentration of Phenindione can be increased when it is combined with Esomeprazole.	Approved, Investigational
Phenobarbital	The metabolism of Esomeprazole can be increased when combined with Phenobarbital.	Approved, Investigational
Phenprocoumon	The serum concentration of Phenprocoumon can be increased when it is combined with Esomeprazole.	Approved, Investigational
Phenytoin	The metabolism of Esomeprazole can be increased when combined with Phenytoin.	Approved, Vet Approved
Piperaquine	The metabolism of Piperaquine can be decreased when combined with Esomeprazole.	Approved, Investigational
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Esomeprazole.	Approved, Investigational
Pitolisant	The serum concentration of Esomeprazole can be decreased when it is combined with Pitolisant.	Approved, Investigational
Podofilox	The metabolism of Podofilox can be decreased when combined with Esomeprazole.	Approved
Posaconazole	The serum concentration of Posaconazole can be decreased when it is combined with Esomeprazole.	Approved, Investigational, Vet Approved
Prasugrel	The metabolism of Prasugrel can be decreased when combined with Esomeprazole.	Approved
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Primidone	The metabolism of Esomeprazole can be increased when combined with Primidone.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Esomeprazole.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Esomeprazole.	Approved
Promazine	The metabolism of Promazine can be decreased when combined with Esomeprazole.	Approved, Vet Approved
Propofol	The metabolism of Propofol can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Esomeprazole.	Approved, Investigational
Quazepam	The metabolism of Quazepam can be decreased when combined with Esomeprazole.	Approved, Illicit
Quetiapine	The metabolism of Quetiapine can be decreased when combined with Esomeprazole.	Approved
Quinine	The metabolism of Quinine can be decreased when combined with Esomeprazole.	Approved
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Esomeprazole.	Approved, Investigational
Raltegravir	The serum concentration of Raltegravir can be increased when it is combined with Esomeprazole.	Approved
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Esomeprazole.	Approved, Investigational
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Esomeprazole.	Approved
Ranolazine	The metabolism of Esomeprazole can be decreased when combined with Ranolazine.	Approved, Investigational
Rifabutin	The metabolism of Esomeprazole can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The serum concentration of Esomeprazole can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The metabolism of Esomeprazole can be increased when combined with Rifapentine.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Esomeprazole.	Approved
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Esomeprazole.	Approved
Risedronate	The serum concentration of Risedronate can be increased when it is combined with Esomeprazole.	Approved, Investigational
Risedronate	The therapeutic efficacy of Risedronate can be decreased when used in combination with Esomeprazole.	Approved, Investigational
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Esomeprazole.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Esomeprazole.	Approved
Rucaparib	The metabolism of Esomeprazole can be decreased when combined with Rucaparib.	Approved, Investigational
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Esomeprazole.	Approved
Saquinavir	The serum concentration of Saquinavir can be increased when it is combined with Esomeprazole.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Esomeprazole can be decreased when used in combination with Sarilumab.	Approved, Investigational
Selegiline	The metabolism of Selegiline can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Esomeprazole.	Approved
Sertraline	The metabolism of Sertraline can be decreased when combined with Esomeprazole.	Approved
Sildenafil	The metabolism of Esomeprazole can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Esomeprazole can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Esomeprazole can be increased when it is combined with Simeprevir.	Approved
St. John's Wort	The serum concentration of Esomeprazole can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Esomeprazole can be increased when it is combined with Stiripentol.	Approved
Sulfisoxazole	The metabolism of Esomeprazole can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Esomeprazole.	Approved, Investigational
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Esomeprazole.	Approved
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Esomeprazole.	Approved
Technetium Tc-99m etidronate	The therapeutic efficacy of Technetium Tc-99m etidronate can be decreased when used in combination with Esomeprazole.	Approved
Technetium Tc-99m medronate	The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Esomeprazole.	Approved
Telaprevir	The metabolism of Esomeprazole can be decreased when combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The metabolism of Esomeprazole can be decreased when combined with Telithromycin.	Approved
Temazepam	The metabolism of Temazepam can be decreased when combined with Esomeprazole.	Approved, Investigational
Teniposide	The metabolism of Teniposide can be decreased when combined with Esomeprazole.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Esomeprazole.	Approved, Investigational, Vet Approved
Testosterone	The metabolism of Testosterone can be decreased when combined with Esomeprazole.	Approved, Investigational
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Esomeprazole.	Approved
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Esomeprazole.	Approved
Testosterone undecanoate	The metabolism of Testosterone undecanoate can be decreased when combined with Esomeprazole.	Approved, Investigational
Thalidomide	The metabolism of Thalidomide can be decreased when combined with Esomeprazole.	Approved, Investigational, Withdrawn
Thioridazine	The metabolism of Thioridazine can be decreased when combined with Esomeprazole.	Approved, Withdrawn
Ticlopidine	The metabolism of Esomeprazole can be decreased when combined with Ticlopidine.	Approved
Tiludronic acid	The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Esomeprazole.	Approved, Investigational, Vet Approved
Timolol	The metabolism of Timolol can be decreased when combined with Esomeprazole.	Approved
Tioclomarol	The serum concentration of Tioclomarol can be increased when it is combined with Esomeprazole.	Experimental
Tipranavir	The serum concentration of Esomeprazole can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tocilizumab	The serum concentration of Esomeprazole can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Esomeprazole.	Approved, Investigational
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Esomeprazole.	Approved, Investigational
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Esomeprazole.	Approved, Investigational
Topiramate	The metabolism of Esomeprazole can be decreased when combined with Topiramate.	Approved
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Esomeprazole.	Approved, Investigational
Tranylcypromine	The metabolism of Esomeprazole can be decreased when combined with Tranylcypromine.	Approved, Investigational
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Esomeprazole.	Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Esomeprazole.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Esomeprazole.	Investigational, Withdrawn
Valproic Acid	The metabolism of Valproic Acid can be decreased when combined with Esomeprazole.	Approved, Investigational
Vemurafenib	The serum concentration of Esomeprazole can be decreased when it is combined with Vemurafenib.	Approved
Venlafaxine	The metabolism of Esomeprazole can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Esomeprazole can be decreased when combined with Verapamil.	Approved
Voriconazole	The serum concentration of Esomeprazole can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Esomeprazole.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Esomeprazole.	Approved
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Esomeprazole.	Approved
Ziprasidone	The metabolism of Esomeprazole can be decreased when combined with Ziprasidone.	Approved
Zoledronic acid	The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Esomeprazole.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Esomeprazole.	Approved
Zucapsaicin	The metabolism of Esomeprazole can be decreased when combined with Zucapsaicin.	Approved, Investigational

Food Interactions

Take without regard to meals.

References

Synthesis Reference

Manne Reddy, "Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof." U.S. Patent US20040167173, issued August 26, 2004.

US20040167173

General References

Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K: Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Jul;14(7):861-7. [PubMed:10886041]

External Links

Human Metabolome Database: HMDB0005009
KEGG Drug: D07917
PubChem Compound: 9568614
PubChem Substance: 46504894
ChemSpider: 7843323
ChEBI: 50275
ChEMBL: CHEMBL1201320
Therapeutic Targets Database: DCL000524
PharmGKB: PA10075
IUPHAR: 4279
Guide to Pharmacology: GtP Drug Page
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Esomeprazole

ATC Codes

M01AE52 — Naproxen and esomeprazole

A02BC05 — Esomeprazole

A02BD06 — Esomeprazole, amoxicillin and clarithromycin

AHFS Codes

56:28.36 — Proton-pump Inhibitors

FDA label

Download (104 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Bone and Bones / Homeostasis	1
1	Completed	Not Available	Endoscopically-Proven GERD / Reflux	1
1	Completed	Not Available	Healthy Volunteers	3
1	Completed	Not Available	Healthy Volunteers / Ilaprazole / Pharmacodynamics / Pharmacokinetics	1
1	Completed	Not Available	Ulcers / Upper GI Symptoms	1
1	Completed	Basic Science	Arthritis	1
1	Completed	Basic Science	Bioequivalence Study	2
1	Completed	Basic Science	Bioequivalence / Healthy Volunteers	1
1	Completed	Basic Science	Gastroesophageal Reflux Disease	1
1	Completed	Basic Science	Healthy Volunteers	9
1	Completed	Basic Science	Healthy Volunteers / Pharmacokinetics of Isavuconazole	1
1	Completed	Basic Science	Juvenile Idiopathic Arthritis (JIA)	1
1	Completed	Other	Healthy Participants	1
1	Completed	Prevention	Peptic Ulcers	1
1	Completed	Supportive Care	Healthy Volunteers	1
1	Completed	Treatment	Dose Finding Study	1
1	Completed	Treatment	Gastro-esophageal Reflux Disease (GERD)	1
1	Completed	Treatment	Healthy Volunteers	5
1	Completed	Treatment	Malignant Lymphomas / Tumors, Solid	1
1	Completed	Treatment	Pharmacokinetics	1
1	Completed	Treatment	Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)	1
1	Enrolling by Invitation	Treatment	Healthy Volunteers	1
1	Not Yet Recruiting	Basic Science	Healthy Volunteers	1
1	Recruiting	Treatment	Gastro-esophageal Reflux Disease (GERD)	1
1	Terminated	Not Available	Peptic Ulcer Disease	1
1	Terminated	Treatment	Exercise Triggered Asthma / Reflux, Gastroesophageal	1
1	Terminated	Treatment	Pancreatitis, Chronic	1
1	Unknown Status	Basic Science	Healthy Volunteers	1
1	Unknown Status	Treatment	Esophagitis / Esophagus, Barrett / Reflux	1
1, 2	Completed	Diagnostic	Tooth Erosion	1
1, 2	Completed	Treatment	Healthy Volunteers With Ileostomy	1
1, 2	Unknown Status	Treatment	Gastro-esophageal Reflux Disease (GERD) / Heartburn / Indigestion	1
2	Completed	Diagnostic	Gastroesophageal Reflux Disease / Reflux, Gastroesophageal	1
2	Completed	Prevention	Esophageal Cancers / Esophagus, Barrett	1
2	Completed	Prevention	Peptic Ulcers	1
2	Completed	Treatment	Asthma Bronchial	1
2	Completed	Treatment	Asthma Bronchial / Gastro-esophageal Reflux Disease (GERD)	1
2	Completed	Treatment	Cancer, Breast / Neoplasms Metastasis	1
2	Completed	Treatment	Erosive Esophagitis(EE) / Gastro-esophageal Reflux Disease (GERD)	1
2	Completed	Treatment	Esophagitis	1
2	Completed	Treatment	Gram-Negative Bacterial Infections / Helicobacter Infections / Indigestion	1
2	Completed	Treatment	Indigestion	2
2	Completed	Treatment	Non-erosive Reflux Disease (NERD)	1
2	Completed	Treatment	Reflux Esophagitis (RE)	1
2	Completed	Treatment	Reflux, Gastroesophageal	1
2	Not Yet Recruiting	Treatment	Acid Dyspepsia / Gastritis	1
2	Recruiting	Prevention	Pain, Neuropathic	1
2	Recruiting	Treatment	Erosive Gastroesophageal Reflux Disease	1
2	Recruiting	Treatment	Gastrointestinal Erosions and/or Ulcers	1
2	Recruiting	Treatment	Reflux, Gastroesophageal	1
2	Terminated	Treatment	Cystic Fibrosis (CF)	1
2	Terminated	Treatment	Gastroesophageal Reflux Disease	1
2	Terminated	Treatment	Hemorrhage, Gastrointestinal	1
2	Unknown Status	Treatment	Gastroesophageal Reflux Disease	1
2, 3	Completed	Treatment	EE / Gastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux Disease / Oesophagitis, Eosinophilic	1
2, 3	Not Yet Recruiting	Treatment	Preeclampsia	1
2, 3	Recruiting	Treatment	Hepatic Encephalopathy	1
2, 3	Unknown Status	Treatment	Gastroesophageal Reflux Disease	1
3	Active Not Recruiting	Prevention	Esophageal Cancers / Precancerous Conditions	1
3	Completed	Not Available	Airway Responsiveness	1
3	Completed	Prevention	Duodenal Ulcer / Gastric Ulcer (GU)	1
3	Completed	Prevention	Duodenal Ulcer / Gastric Ulcer (GU) / Low Back Pain (LBP) / Osteoarthritis (OA) / Rheumatoid Arthritis	2
3	Completed	Prevention	ERCP / Haemorrhage	1
3	Completed	Prevention	Hemorrhage, Gastrointestinal	1
3	Completed	Prevention	NSAID Associated Gastric Ulcers	2
3	Completed	Prevention	Peptic ulcer haemorrhage	1
3	Completed	Prevention	Prevention	1
3	Completed	Prevention	Reflux, Gastroesophageal	1
3	Completed	Prevention	Stress Ulcer Prophylaxis	1
3	Completed	Treatment	Arthritis / Bleeding Ulcers	1
3	Completed	Treatment	Asthma Bronchial	1
3	Completed	Treatment	Asthma Bronchial / Chronic Lung Diseases / Lung Diseases, Obstructive	1
3	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
3	Completed	Treatment	Erosive Esophagitis(EE)	2
3	Completed	Treatment	Gastric Ulcer (GU)	4
3	Completed	Treatment	Gastro-esophageal Reflux Disease (GERD)	7
3	Completed	Treatment	Gastroesophageal Reflux Disease	2
3	Completed	Treatment	Gastrointestinal Diseases / Indigestion / Signs and Symptoms, Digestive	2
3	Completed	Treatment	Haemorrhage / Peptic Ulcers	1
3	Completed	Treatment	Healthy Volunteers	1
3	Completed	Treatment	Heartburn	2
3	Completed	Treatment	Heartburn / Indigestion / Reflux, Gastroesophageal	1
3	Completed	Treatment	Hemorrhage, Gastrointestinal	1
3	Completed	Treatment	Hypercholesterolemia, Familial	1
3	Completed	Treatment	NSAID Associated Gastric Ulcers	2
3	Completed	Treatment	NSAIDs / Upper GI Symptoms	2
3	Completed	Treatment	Osteoarthritis (OA)	2
3	Completed	Treatment	Reflux Esophagitis (RE)	2
3	Completed	Treatment	Reflux, Gastroesophageal	2
3	Completed	Treatment	Reflux, Gastroesophageal / Thoracic Pain	1
3	Completed	Treatment	Symptomatic Gastroesophageal Reflux Disease (sGERD)	1
3	Completed	Treatment	Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Zollinger-Ellison Syndrome	1
3	Not Yet Recruiting	Treatment	Sepsis / Shock, Septic	1
3	Recruiting	Treatment	Acute and Chronic Inflammation / Indigestion	1
3	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
3	Recruiting	Treatment	Dry Eye Syndrome (DES) / Ophthalmopathy, Thyroid-Associated	1
3	Recruiting	Treatment	Indigestion	1
3	Terminated	Treatment	Gastric Ulcer (GU)	1
3	Terminated	Treatment	Nausea	1
3	Unknown Status	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori) / Chronic Gastritis	1
3	Unknown Status	Treatment	Gastro-esophageal Reflux Disease (GERD)	1
3	Unknown Status	Treatment	Lymphocytic Gastritis	1
3	Withdrawn	Treatment	Gastroesophageal Reflux Disease	1
3	Withdrawn	Treatment	Larynx Disease	1
4	Active Not Recruiting	Treatment	Helicobacter Pylori Gastrointestinal Tract Infection	1
4	Completed	Not Available	Erosive Esophagitis(EE) / Gastroesophageal Reflux Disease / Reflux Esophagitis (RE)	1
4	Completed	Not Available	Healthy Volunteers	2
4	Completed	Basic Science	Heartburn	1
4	Completed	Diagnostic	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Completed	Diagnostic	Gastro-esophageal Reflux Disease (GERD)	1
4	Completed	Diagnostic	Reflux, Gastroesophageal	1
4	Completed	Prevention	Abdominal Pain (AP) / Nausea / Vomiting	1
4	Completed	Prevention	Postoperative Bariatric Surgery	1
4	Completed	Prevention	Ulcers	1
4	Completed	Supportive Care	Impacted Third Molar Tooth / Other Surgical Procedures / Pain	1
4	Completed	Treatment	Acid Regurgitation / Heartburn / Nausea / Upper Abdominal Pain	1
4	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	3
4	Completed	Treatment	Chronic Gastritis / Non Erosive Reflux Disease	1
4	Completed	Treatment	Chronic Posterior Laryngitis (CPL)	1
4	Completed	Treatment	Colorectal Cancers	1
4	Completed	Treatment	Coughing / Gastro-esophageal Reflux Disease (GERD)	1
4	Completed	Treatment	Critically Ill Patients / Indication for Stress Ulcer Prophylaxis	1
4	Completed	Treatment	Erosive Esophagitis(EE)	3
4	Completed	Treatment	Erosive Esophagitis(EE) / Gastro-esophageal Reflux Disease (GERD) / Non-erosive Esophagitis	1
4	Completed	Treatment	Esophagus, Barrett	3
4	Completed	Treatment	Functional Dyspepsia / Helicobacter Pylori / Peptic Ulcers	1
4	Completed	Treatment	Gastric Ulcer (GU)	1
4	Completed	Treatment	Gastritis / Indigestion / Peptic Ulcers	1
4	Completed	Treatment	Gastro-Oesophageal Reflux	1
4	Completed	Treatment	Gastro-esophageal Reflux Disease (GERD)	8
4	Completed	Treatment	Gastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux Disease / Reflux Esophagitis (RE)	1
4	Completed	Treatment	Gastroesophageal Reflux Disease	7
4	Completed	Treatment	Gastroesophageal Reflux Disease / Heartburn	1
4	Completed	Treatment	Healthy Volunteers	1
4	Completed	Treatment	Heartburn	2
4	Completed	Treatment	Heartburn / Reflux, Gastroesophageal	1
4	Completed	Treatment	Helicobacter Infection	1
4	Completed	Treatment	Helicobacter Infections	1
4	Completed	Treatment	Indigestion	2
4	Completed	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
4	Completed	Treatment	NSAID Induced Gastropathy	1
4	Completed	Treatment	Peptic Ulcer Bleeding	1
4	Completed	Treatment	Reflux, Gastroesophageal	2
4	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
4	Completed	Treatment	Schizophrenic Disorders	1
4	Completed	Treatment	Bone destruction	1
4	Not Yet Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Not Yet Recruiting	Treatment	Helicobacter Pylori Gastrointestinal Tract Infection	1
4	Not Yet Recruiting	Treatment	Psoriasis	1
4	Recruiting	Diagnostic	Indigestion / Reflux, Gastroesophageal	1
4	Recruiting	Prevention	Acid-related Symptoms / Stomach Diseases	1
4	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	8
4	Recruiting	Treatment	Indigestion	1
4	Recruiting	Treatment	Laryngopharyngeal Reflux	1
4	Recruiting	Treatment	Osteoarthritis (OA)	1
4	Terminated	Treatment	Indigestion	1
4	Unknown Status	Screening	30 Healthy People	1
4	Unknown Status	Treatment	Aspirin / Indigestion	1
4	Unknown Status	Treatment	Gastroesophageal Reflux Disease / Heartburn / Sleep Disturbances	1
4	Unknown Status	Treatment	Gastroesophageal Refluxdisease / Indigestion / Ulcers	1
4	Unknown Status	Treatment	Healthy Volunteers	1
4	Unknown Status	Treatment	Nonulcer Dyspepsia	1
4	Unknown Status	Treatment	Peptic Ulcers	1
4	Unknown Status	Treatment	Upper Gastrointestinal Hemorrhage	2
4	Withdrawn	Prevention	Anastomotic Stricture / Obesity, Morbid	1
4	Withdrawn	Treatment	Peptic Ulcers	1
Not Available	Completed	Not Available	Community Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)	1
Not Available	Completed	Not Available	Gastro-esophageal Reflux Disease (GERD) / Quality of Life	1
Not Available	Completed	Not Available	Pharmacokinetics / Voriconazole	1
Not Available	Completed	Basic Science	Reflux, Gastroesophageal	1
Not Available	Completed	Diagnostic	Gastro-esophageal Reflux Disease (GERD)	1
Not Available	Completed	Diagnostic	Gastroesophageal Reflux Disease	1
Not Available	Completed	Health Services Research	Gastro-esophageal Reflux Disease (GERD)	1
Not Available	Completed	Prevention	Stomach Neoplasms	1
Not Available	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
Not Available	Completed	Treatment	Gastritis	1
Not Available	Completed	Treatment	Laryngopharyngeal Reflux / Oesophageal pH-impedance	1
Not Available	Completed	Treatment	Oesophagitis, Eosinophilic	1
Not Available	Completed	Treatment	Reflux, Gastroesophageal	1
Not Available	Completed	Treatment	Treatment of Helicobacter Pylori	1
Not Available	Completed	Treatment	Vasomotor Rhinitis	1
Not Available	Not Yet Recruiting	Treatment	Gastroesophageal Reflux Disease	1
Not Available	Recruiting	Not Available	Reflux, Gastroesophageal	1
Not Available	Recruiting	Diagnostic	Non-erosive Reflux Disease (NERD)	1
Not Available	Recruiting	Diagnostic	Non-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal	1
Not Available	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	2
Not Available	Recruiting	Treatment	Gastric Peroral Endoscopic Pyloromyotomy (G-POEM)	1
Not Available	Recruiting	Treatment	Helicobacter Infection	1
Not Available	Terminated	Diagnostic	Achalasia / GORD	1
Not Available	Terminated	Prevention	Esophagus, Barrett	1
Not Available	Terminated	Treatment	Duodenal Ulcer Induced by Anti-platelet Agent / Gastric Ulcer Induced by Anti-platelet Agent / OGD	1
Not Available	Terminated	Treatment	Gastro-Esophageal Reflux	1
Not Available	Unknown Status	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
Not Available	Unknown Status	Treatment	Hemostasis / Hexacapron / Mortality / Rebleeding / Upper Gastrointestinal Hemorrhage	1

Pharmacoeconomics

Manufacturers

Astrazeneca lp

Packagers

AQ Pharmaceuticals Inc.
A-S Medication Solutions LLC
AstraZeneca Inc.
Cardinal Health
Direct Pharmaceuticals Inc.
Diversified Healthcare Services Inc.
Innoviant Pharmacy Inc.
Lake Erie Medical and Surgical Supply
Merck & Co.
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Physicians Total Care Inc.
Prepackage Specialists
Rebel Distributors Corp.
Southwood Pharmaceuticals
Stat Rx Usa

Dosage forms

Form	Route	Strength
Capsule, delayed release	Oral	20 mg/1
Capsule, delayed release	Oral	20 1/1
Capsule, delayed release	Oral	40 1/1
Capsule, delayed release	Oral	40 mg/1
Capsule, delayed release pellets	Oral	20 mg/1
Capsule, delayed release pellets	Oral	40 mg/1
Injection, powder, lyophilized, for solution	Intravenous	20 mg/1
Injection, powder, lyophilized, for solution	Intravenous	20 mg/5mL
Injection, powder, lyophilized, for solution	Intravenous	40 mg/5mL
Injection, powder, lyophilized, for solution	Intravenous	40 mg/1
Capsule, delayed release	Oral	24.65 mg/1
Capsule, delayed release	Oral	49.3 mg/1
Granule, delayed release	Oral	10 mg/1
Granule, delayed release	Oral	10 mg
Granule, delayed release	Oral	2.5 mg/1
Granule, delayed release	Oral	20 mg/1
Granule, delayed release	Oral	40 mg/1
Granule, delayed release	Oral	5 mg/1
Tablet, delayed release	Oral	20 mg
Tablet, delayed release	Oral	40 mg
Tablet	Oral	20 mg/1
Injection	Intravenous	20 mg/5mL
Injection	Intravenous	40 mg/5mL
Kit
Capsule, delayed release	Oral	20 mg
Capsule, delayed release	Oral	40 mg
Tablet, delayed release	Oral

Prices

Unit description	Cost	Unit
Nexium i.v. 20 mg vial	33.91USD	vial
Nexium i.v. 40 mg vial	33.91USD	vial
NexIUM 20 mg Delayed Release Capsule	6.76USD	capsule
NexIUM 40 mg Delayed Release Capsule	6.76USD	capsule
Nexium 10 mg packet	6.5USD	each
Nexium 20 mg capsule	6.5USD	capsule
Nexium 20 mg packet	6.5USD	each
Nexium 40 mg capsule	6.5USD	capsule
Nexium 40 mg packet	6.5USD	each

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5877192	No	1994-05-27	2014-05-27
CA1338377	No	1996-06-11	2013-06-11
CA2346988	No	2009-02-10	2019-11-03
US6191148	Yes	1999-04-09	2019-04-09
US6147103	Yes	1999-04-09	2019-04-09
US6166213	Yes	1999-04-09	2019-04-09
US5900424	Yes	1996-11-04	2016-11-04
US6369085	Yes	1998-11-25	2018-11-25
US6428810	Yes	2000-05-03	2020-05-03
US7411070	Yes	1998-11-25	2018-11-25
US8466175	Yes	1998-11-25	2018-11-25
US8852636	No	2002-05-31	2022-05-31
US8858996	No	2002-05-31	2022-05-31
US6926907	No	2003-02-28	2023-02-28
US7745466	No	1998-10-13	2018-10-13
US9161920	No	2002-05-31	2022-05-31
US9198888	No	2002-05-31	2022-05-31
US8945621	No	2011-10-17	2031-10-17
US8557285	No	2002-05-31	2022-05-31
US9220698	No	2011-03-10	2031-03-10
US5714504	Yes	1995-08-03	2015-08-03
US9345695	No	2002-05-31	2022-05-31
US9393208	No	2009-09-03	2029-09-03
US9707181	No	2002-05-31	2022-05-31

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	155 °C	Not Available
water solubility	Very slightly soluble in water	Not Available
logP	0.6	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.353 mg/mL	ALOGPS
logP	1.66	ALOGPS
logP	2.43	ChemAxon
logS	-3	ALOGPS
pKa (Strongest Acidic)	9.68	ChemAxon
pKa (Strongest Basic)	4.77	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	77.1 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	93.66 m³·mol^-1	ChemAxon
Polarizability	35.81 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9968
Blood Brain Barrier	-	0.6326
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Non-substrate	0.5573
P-glycoprotein inhibitor I	Inhibitor	0.6622
P-glycoprotein inhibitor II	Non-inhibitor	0.968
Renal organic cation transporter	Non-inhibitor	0.542
CYP450 2C9 substrate	Non-substrate	0.7838
CYP450 2D6 substrate	Substrate	0.6175
CYP450 3A4 substrate	Substrate	0.6901
CYP450 1A2 substrate	Inhibitor	0.7505
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Inhibitor	0.8994
CYP450 3A4 inhibitor	Inhibitor	0.796
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.7895
Ames test	Non AMES toxic	0.5692
Carcinogenicity	Non-carcinogens	0.8318
Biodegradation	Not ready biodegradable	0.9778
Rat acute toxicity	2.2254 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.719
hERG inhibition (predictor II)	Non-inhibitor	0.8977

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Benzimidazoles
Sub Class: Sulfinylbenzimidazoles
Direct Parent: Sulfinylbenzimidazoles
Alternative Parents: Anisoles / Methylpyridines / Alkyl aryl ethers / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents: Sulfinylbenzimidazole / Anisole / Alkyl aryl ether / Methylpyridine / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide
show 12 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole (CHEBI:50275)

Targets

Details1. Potassium-transporting ATPase alpha chain 1

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Sodium:potassium-exchanging atpase activity
Specific Function: Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name: ATP4A
Uniprot ID: P20648
Uniprot Name: Potassium-transporting ATPase alpha chain 1
Molecular Weight: 114117.74 Da

References

Saccar CL: The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. doi: 10.1517/17425250903124363. [PubMed:19606942]
McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM: Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs. 2008;68(11):1571-607. [PubMed:18627213]
Vachhani R, Olds G, Velanovich V: Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):15-27. doi: 10.1586/17474124.3.1.15. [PubMed:19210109]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Details1. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Klotz U: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006 Jul;44(7):297-302. [PubMed:16961157]

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:17

Esomeprazole

Identification

Structure for DB00736 (Esomeprazole)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References